KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Depreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsReceivables - Other
Ratios

TherapeuticsMD (TXMD) Depreciation & Amortization (IS) (2016 - 2025)

TherapeuticsMD's Depreciation & Amortization (IS) history spans 13 years, with the latest figure at $97000.0 for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (IS) fell 3.0% year-over-year to $97000.0; the TTM value through Dec 2025 reached $384000.0, down 24.56%, while the annual FY2025 figure was $384000.0, 24.56% down from the prior year.
  • Depreciation & Amortization (IS) reached $97000.0 in Q4 2025 per TXMD's latest filing, up from $96000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (IS) ranged from a high of $637000.0 in Q4 2023 to a low of $27000.0 in Q1 2023.
  • Average Depreciation & Amortization (IS) over 3 years is $151250.0, with a median of $98500.0 recorded in 2024.
  • The largest YoY upside for Depreciation & Amortization (IS) was 392.59% in 2024 against a maximum downside of 84.3% in 2024.
  • A 3-year view of Depreciation & Amortization (IS) shows it stood at $637000.0 in 2023, then plummeted by 84.3% to $100000.0 in 2024, then decreased by 3.0% to $97000.0 in 2025.
  • Per Business Quant, the three most recent readings for TXMD's Depreciation & Amortization (IS) are $97000.0 (Q4 2025), $96000.0 (Q3 2025), and $96000.0 (Q2 2025).